Title |
Long-Term Statin Treatment in Children with Familial Hypercholesterolemia: More Insight into Tolerability and Adherence
|
---|---|
Published in |
Pediatric Drugs, February 2015
|
DOI | 10.1007/s40272-014-0116-y |
Pubmed ID | |
Authors |
Marjet J. A. M. Braamskamp, D. Meeike Kusters, Hans J. Avis, Ellen M. A. Smets, Frits A. Wijburg, John J. P. Kastelein, Albert Wiegman, Barbara A. Hutten |
Abstract |
Statins are currently the preferred pharmacological therapy in individuals with familial hypercholesterolemia (FH) with the aim to prevent premature atherosclerosis. In adults, these agents have been proven to be safe and well tolerated; however, non-adherence is a significant clinical issue. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 5 | 83% |
Unknown | 1 | 17% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 3 | 50% |
Members of the public | 2 | 33% |
Science communicators (journalists, bloggers, editors) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 1% |
Unknown | 66 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 10 | 15% |
Student > Ph. D. Student | 9 | 13% |
Student > Master | 8 | 12% |
Student > Bachelor | 6 | 9% |
Student > Doctoral Student | 5 | 7% |
Other | 15 | 22% |
Unknown | 14 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 27 | 40% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 10% |
Nursing and Health Professions | 3 | 4% |
Agricultural and Biological Sciences | 2 | 3% |
Unspecified | 2 | 3% |
Other | 6 | 9% |
Unknown | 20 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2015.
All research outputs
#6,229,748
of 22,786,087 outputs
Outputs from Pediatric Drugs
#143
of 551 outputs
Outputs of similar age
#85,910
of 352,352 outputs
Outputs of similar age from Pediatric Drugs
#3
of 8 outputs
Altmetric has tracked 22,786,087 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 551 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,352 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.